Meitav Investment House Ltd. Increases Stake in Johnson & Johnson (NYSE:JNJ)

Meitav Investment House Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,361 shares of the company’s stock after buying an additional 210 shares during the quarter. Meitav Investment House Ltd.’s holdings in Johnson & Johnson were worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atlantic Private Wealth LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $32,000. 25 LLC bought a new stake in Johnson & Johnson during the first quarter worth about $55,000. Horizons Wealth Management boosted its stake in Johnson & Johnson by 1,730.0% during the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock worth $61,000 after acquiring an additional 346 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the second quarter worth about $66,000. Finally, Mcmillion Capital Management Inc. bought a new stake in Johnson & Johnson during the second quarter worth about $103,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

JNJ opened at $149.91 on Tuesday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $181.04. The stock has a market capitalization of $360.88 billion, a price-to-earnings ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a 50 day moving average price of $154.52 and a 200-day moving average price of $160.29.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The business had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. Equities research analysts forecast that Johnson & Johnson will post 10.1 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be paid a $1.19 dividend. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 35.34%.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Friday. Barclays boosted their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 12th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 26th. Atlantic Securities upped their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.